Cellular Signaling in Drug-induced Toxicity
药物引起的毒性中的细胞信号转导
基本信息
- 批准号:8636492
- 负责人:
- 金额:$ 30.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylcysteineAcute Liver FailureAdverse eventAnabolismAnti-Retroviral AgentsAntioxidantsAntiviral AgentsApoptosisApoptoticAttenuatedBIM Bcl-2-binding proteinBax proteinBiochemicalBiological AssayBiological ModelsBoxingCell DeathCessation of lifeClinical MarkersCoupledDataEnzymesEventExhibitsGene Expression ProfilingGenesGeneticGenetic TranscriptionGlutathioneGoalsHepatocyteHepatotoxicityHistologyHumanImmunoblottingIn VitroInfectionKnockout MiceLeadMacacaMass Spectrum AnalysisMeasuresMediatingMetabolismModelingMolecularMusNevirapineOxidative StressParentsPathway interactionsPatientsPharmaceutical PreparationsPreventionPrevention strategyProteinsPurine NucleotidesRNA InterferenceReporter GenesReportingResistanceRitonavirRodentRoleSamplingSignal PathwaySignal TransductionSmall Interfering RNATechniquesTestingTherapeuticToxic effectUp-RegulationVirus DiseasesWorkantiretroviral therapybasecytotoxicityefavirenzglucose metabolismin vitro Modelin vivoinhibitor/antagonistliquid chromatography mass spectrometryliver injurymRNA Expressionmetabolomicsnew therapeutic targetnovelnovel strategiespreventprotein expressionpublic health relevanceresearch study
项目摘要
DESCRIPTION (provided by applicant): Efavirenz (EFV) and nevirapine (NVP) are currently prescribed antiretroviral drugs of the same class that are hepatotoxic. Recently, a major role for cellular signaling pathways in modulating toxicity downstream of EFV metabolism has been reported in vitro using primary human hepatocytes. Increased oxidative stress and the upregulation of the proapoptotic protein BimEL (Bcl-2 interacting mediator of cell death extra long) have been demonstrated to be crucial in the stimulation of EFV-induced cell death, and NVP appears to modulate hepatocyte death via the same mechanism. The goal of this proposal is to determine the manner in which EFV and NVP upregulate BimEL, while also gaining a mechanistic understanding of the events downstream of BimEL that mediate the hepatocyte death. The aims are as follows: (1) Test whether genetic deficiency of proapoptotic BimEL results in protection against EFV- and NVP-mediated cell death in vivo: BimEL null mice will be used to determine whether the absence of BimEL renders mice resistant to hepatotoxicity stimulated by these compounds; RNA interference studies in hepatocytes will be used to determine the role of effector proteins, Bax and Bak, that are downstream of BimEL in modulating EFV- and NVP-induced hepatocyte death; siRNA and reporter gene assays will be used to define the mechanism by which EFV and NVP regulate the transcription of BimEL; (2) determine if proapoptotic pathways that are activated by antiretrovirals in primary human hepatocytes are also activated in macaques receiving antiretroviral therapy; (3) probe a role for alteration of the glutathione pathway in EFV- and NVP-induced hepatotoxicity; the effects of these compounds on the glutathione pathway will be examined using a mass spectrometry-based approach that will precisely quantitate the intermediates/products of this pathway; RNA interference will be used to define the role of enzymes in the glutathione pathway in EFV- and NVP-induced hepatotoxicity. It is expected that completion of the proposed studies will lead to the identification of novel therapeutic targets for the potential prevention and treatment of EFV- and NVP-mediated hepatotoxicity.
描述(由申请方提供):依法韦仑(EFV)和奈韦拉平(NVP)是目前处方的肝毒性同类抗逆转录病毒药物。最近,在体外使用原代人肝细胞报道了细胞信号传导途径在调节EFV代谢下游毒性中的主要作用。氧化应激的增加和促凋亡蛋白BimEL(Bcl-2相互作用的细胞死亡介质超长)的上调已被证明是至关重要的刺激EFV诱导的细胞死亡,NVP似乎通过相同的机制调节肝细胞死亡。该提案的目标是确定EFV和NVP上调BimEL的方式,同时也获得对介导肝细胞死亡的BimEL下游事件的机制理解。其目标如下:(1)测试促凋亡BimEL的遗传缺陷是否导致体内针对EFV和NVP介导的细胞死亡的保护:BimEL缺失小鼠将用于确定BimEL的缺失是否使小鼠对这些化合物刺激的肝毒性具有抗性;肝细胞中的RNA干扰研究将用于确定效应蛋白Bax和巴克的作用,在调节EFV和NVP诱导的肝细胞死亡中位于BimEL的下游; siRNA和报告基因测定将用于确定EFV和NVP调节BimEL转录的机制;(2)确定在原代人肝细胞中被抗逆转录病毒激活的促凋亡途径是否也在接受抗逆转录病毒治疗的猕猴中被激活;(3)探索谷胱甘肽途径在EFV和NVP诱导的肝毒性中的改变作用;将使用基于质谱的方法检查这些化合物对谷胱甘肽途径的影响,该方法将精确定量该途径的中间体/产物; RNA干扰将用于确定酶在谷胱甘肽途径中在EFV和NVP诱导的肝毒性中的作用。预计完成拟定研究将导致确定用于预防和治疗EFV和NVP介导的肝毒性的新型治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Namandje N Bumpus其他文献
Namandje N Bumpus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Namandje N Bumpus', 18)}}的其他基金
Developmental Pharmacology of Antiretroviral Metabolism in Mucosal Tissues
粘膜组织中抗逆转录病毒代谢的发育药理学
- 批准号:
9244420 - 财政年份:2017
- 资助金额:
$ 30.78万 - 项目类别:
相似海外基金
Senescent hepatocytes mediate reprogramming of immune cells in acute liver failure
衰老肝细胞介导急性肝衰竭中免疫细胞的重编程
- 批准号:
10679938 - 财政年份:2023
- 资助金额:
$ 30.78万 - 项目类别:
Hepatocytes Encapsulated with mesenchymal stromal cells in alginate microbeads for the treatment of acute Liver failure in Paediatric patients (HELP)
将间充质基质细胞封装在藻酸盐微珠中的肝细胞用于治疗儿科患者的急性肝衰竭(HELP)
- 批准号:
MR/V038583/1 - 财政年份:2022
- 资助金额:
$ 30.78万 - 项目类别:
Research Grant
Development of the innovative treatment using self iPS cell for acute liver failure
开发利用自身 iPS 细胞治疗急性肝衰竭的创新疗法
- 批准号:
21K08685 - 财政年份:2021
- 资助金额:
$ 30.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
- 批准号:
10421290 - 财政年份:2021
- 资助金额:
$ 30.78万 - 项目类别:
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
- 批准号:
10180251 - 财政年份:2021
- 资助金额:
$ 30.78万 - 项目类别:
Therapeutic effect of plasmacytoid dendritic cells transplantation for acute liver failure
浆细胞样树突状细胞移植治疗急性肝衰竭的疗效
- 批准号:
20K21607 - 财政年份:2020
- 资助金额:
$ 30.78万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Macrophage Therapy for Acute Liver Failure
巨噬细胞治疗急性肝衰竭
- 批准号:
MR/T044802/1 - 财政年份:2020
- 资助金额:
$ 30.78万 - 项目类别:
Research Grant
Investigation of an optimal environment for the proliferation of mature hepatocytes toward the rescue of acute liver failure patients
研究成熟肝细胞增殖的最佳环境以挽救急性肝衰竭患者
- 批准号:
19K08475 - 财政年份:2019
- 资助金额:
$ 30.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pediatric Acute Liver Failure (PALF) TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
小儿急性肝衰竭 (PALF) 免疫介导病理生理学治疗 (TRIUMPH)
- 批准号:
9789253 - 财政年份:2018
- 资助金额:
$ 30.78万 - 项目类别:
Cryopreservation of hiPS-derivd hepatic progenitor cells and application to acute liver failure treatment
hiPS源性肝祖细胞的冷冻保存及其在急性肝衰竭治疗中的应用
- 批准号:
18K08662 - 财政年份:2018
- 资助金额:
$ 30.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)